Generic form of antibiotic for CF lung infections wins FDA approval
Tobramycin inhalation solution offers affordable option to patients 6 and older by Marisa Wexler, MS The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin , an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its generics division, Ritedose Pharmaceuticals. It is indicated to tr
Dual-action therapy for cystic fibrosis shows promise: Study
Experimental compound 3b addresses disease itself, viral threats by Michela Luciano, PhD | Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In lab tests, compound 3b restored CFTR activity, blocked the growth of several resp
Chronic health conditions and food insecurity in kids
Study shows children with chronic conditions may face higher risk of food insecurity A recent Michigan Medicine-led study finds a link...
SoftOx Solutions Advances Cystic Fibrosis Treatment with New Clinical Trial Application
Story by TipRanks European Auto-Generated Newsdesk https://www.tipranks.com/news/company-announcements/softox-solutions-advances-cystic-f...
Cystic Fibrosis and Seasonal Respiratory Illnesses: Flu, COVID-19, and RSV
The flu, COVID-19, and RSV are highly contagious viruses that can cause significant illness. When people with cystic fibrosis get one of...
Trikafta benefits seen regardless of prior CFTR modulator use for CF
Real world study shows approved medication eased symptoms over 1 year by Lila Levinson, PhD | One-year treatment with Trikafta — a...
